Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNG2 | P59768 | 5/20 | 0.80 |
| ▸ | GNB1 | P62873 | 5/20 | 0.80 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.66 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.66 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.66 |
| ▸ | MET | P08581 | 2/20 | 0.65 |
| ▸ | HGF | P14210 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10708708 | 0.93 | GNG2 (0.84) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL13021512 | 0.93 | GNG2 (0.92) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL3026032 | 0.92 | GNG2 (0.82) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL11415305 | 0.89 | GNG2 (0.78) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL13213975 | 0.89 | GNG2 (0.86) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL2778161 | 0.89 | GNG2 (1.00) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL29354288 | 0.89 | GNG2 (1.00) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL791019 | 0.89 | GNG2 (0.85) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL29357302 | 0.89 | GNG2 (0.85) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL2781947 | 0.88 | GNG2 (1.00) | GNG2GNB1PHLPP2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238718-B2 | Method for treating myolytic disease and method for screening antimyolytic agent | OSAKA BIOSCIENCE INSTITUTE (JP) | 2007-07-03 | — | — | US | claimed |
| US-20050272767-A1 | Method for treating myolytic disease and method for screening antimyolytic agent | OSAKA BIOSCIENCE INSTITUTE AND RIKEN (JP) | 2005-12-08 | — | — | US | claimed |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | claimed |
| EP-1535629-A1 | DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME | Japan Science and Technology Agency (JP) | 2005-06-01 | — | — | EP | claimed |
| US-8568967-B2 | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-1882937-B1 | METHOD FOR DIAGNOSIS OF SEVERITY AND PREDICTION OF RECURRENCE IN EOSINOPHILIC INFLAMMATORY DISEASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20100138937-A1 | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease | AROS ELECTRONICS AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1882937-A1 | METHOD FOR DIAGNOSIS OF SEVERITY AND PREDICTION OF RECURRENCE IN EOSINOPHILIC INFLAMMATORY DISEASE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-7238718-B2 | Method for treating myolytic disease and method for screening antimyolytic agent | OSAKA BIOSCIENCE INSTITUTE (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20050272767-A1 | Method for treating myolytic disease and method for screening antimyolytic agent | OSAKA BIOSCIENCE INSTITUTE AND RIKEN (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1598065-A2 | Drugs for improving prognosis of brain injury | Japan Science and Technology Agency (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | SHIONOGI & CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1535629-A1 | DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME | Japan Science and Technology Agency (JP) | 2005-06-01 | — | — | EP | disclosed |
| JP-2004002248-A | HUMAN-ORIGINATED PROSTAGRANDIN-SYNTHESIZING ENZYME INHIBITOR | JAPAN SCIENCE & TECHNOLOGY CORP | 2004-01-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | GNG2 1783/4885GNB1 1888/4885PHLPP2 3324/4885 |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | GNG2 1783/4885GNB1 1888/4885PHLPP2 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.